Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

This study has been terminated.
(closed to enrollment)
Sponsor:
Information provided by:
CTI BioPharma
ClinicalTrials.gov Identifier:
NCT00577161
First received: December 17, 2007
Last updated: September 19, 2008
Last verified: September 2008
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2012
  Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)